Report Overview

The global heart attack diagnostics market was pegged at US$ 12.45 billion in 2021 and is expected to witness a CAGR of 7.9% during the forecast period.

Market Fundamentals 

Heart attack, or myocardial infraction, is a kind of cardiovascular disease (CVD) that develops when oxygenated blood supply to the heart muscles is reduced or interrupted. The prevalence of chronic illnesses like diabetes and hypertension is growing. Numerous risk factors, including a high body mass index, a transition to an unhealthy lifestyle, and smoking promote atherosclerosis and constrict the coronary arteries as a result of fat deposition and high cholesterol levels. Heart attack diagnostics are in high demand in the healthcare systems worldwide since myocardial ischemia is one of the leading causes of mortality.

[123456]

Market Dynamics

The increased need for ongoing patient monitoring, patient accessibility, changing lifestyles, rising R&D expenditures, and technical innovation have all contributed to the surge in demand for heart attack diagnostic tools. For instance, according to World Health Organisation (WHO), heart attack caused around 17.9 million deaths globally (2019). Coronary Artery Disorders (CADs) are a major cause of heart attack. Symptoms related to heart attach include acute and intense chest pain, pain in neck, and shortness of breath. 

Additionally, a number of governments and international organisations are raising public awareness of surveillance devices. The market for heart attack diagnostics is driven by several factors, but a few are anticipated to continue to constrain in market growth in the near future, such as the low Medicare payments for peripatetic cardiac outpatient telemetry electrocardiograms (ECG).

Market Ecosystem

The global heart attack diagnostics market has been analysed by four perspectives by test, type, end user and region.

Heart Attack Diagnostics Market by Test

[234678]

Based on test types, the global heart attack diagnostics market has been segmented into electrocardiography (ECG), blood tests, computerized cardiac tomography, echocardiography, coronary angiography, magnetic resonance imaging and others. The ECG segment dominated the market during forecast period due to rapid technical advancements and an increase in ECG applications, developing nations are predicted to see a large growth rate in the ECG market. Even yet, the market share of inexpensive, quick blood tests like troponin and Creatine Kinase MB Isoenzyme (CK-MB) is projected to grow significantly in the near future.

Heart Attack Diagnostics Market by Type

On the basis of type, the global heart attack diagnostics market has been segmented into minimally invasive and non-invasive. The non-invasive segment is anticipated to experience robust revenue growth over the forecast period due to more technologically advanced non-invasive diagnostic imaging modalities are used to provide high-resolution images for precise diagnosis of coronary artery disease and real-time visualisation of arterial wall.

Heart Attack Diagnostics Market by End User

Based on end user, the global heart attack diagnostics market has been segmented into hospital & clinics, diagnostic centres and ambulatory surgical centres. The hospital & clinics segment is anticipated to take the lead in terms of revenue share over the forecast period due to the rising number of coronary artery bypass grafting and transcatheter structural heart surgery procedures carried out in hospitals to diagnose and treat coronary artery disease.

Heart Attack Diagnostics Market by Region

Based on the region, the global heart attack diagnostics market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. The largest revenue share is anticipated to come from North America over the forecast period, which can be attributed to the region's ageing population, rising demand for advanced diagnostic imaging techniques, and rising R&D spending aimed at enhancing heart disease detection and screening as well as contributing to better diagnosis and facilitating decision marking in targeted treatment.

Competitive Landscape

Some of the key players operating the global heart attack diagnostics market include

• Siemens Healthineers AG
• Schiller AG
• AstraZeneca PLC
• GE Healthcare Inc.
• F. Hoffman La-Roche Ltd. 
• Koninklijke Philips N.V. 
• Welch Allyn Inc. 
• Canon Medical Systems Corporation
• Bio-Rad Laboratories Inc. 
• Toshiba International Corporation
• Abbott Laboratories Inc. 
• Danaher Corporation 

Many of these key companies are actively engaging in various marketing tactics as well as research and development initiatives to create new technologies. For instance, in May 2019, Abbott introduced a brand-new implantable cardiac monitor (ICM) device that allowed users to see their heartbeat. CARDIOVIT FT-1, created by Schiller AG in August 2015, has proven effective for ongoing heartbeat monitoring.

Strategic Developments

• July 2021, in order to promote the use of cardiac CT and establish a new standard of care for heart illness, Canon Medical and Cleerly have partnered up. Major improvements in cardiac diagnosis will result from this partnership.
• June 2021, Selatogrel-based phase 3 registration study is being started by Idorsia. Aspirin might eventually give way to seltogrel. Phase 3 will assess the effectiveness and safety of selatogrel. 
• In April 2021, Roche introduced a pair of vital cardiac biomarkers known as cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test using its Elecsys technology.
• In September 2019, Abbott released the RX Implantable Cardiac Monitor (ICM). This monitor keeps track of cardiac rhythm by watching the heartbeat and with least disturbance or interruption to patients because of its discreet size and smartphone connectivity.

Frequently Asked Questions About This Report